These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 1410575

  • 21. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
    Patterson AV, Saunders MP, Chinje EC, Talbot DC, Harris AL, Strafford IJ.
    Br J Cancer; 1997; 76(10):1338-47. PubMed ID: 9374381
    [Abstract] [Full Text] [Related]

  • 22. Effect of interstitial and/or systemic delivery of tirapazamine on the radiosensitivity of human glioblastoma multiforme in nude mice.
    Cardinale RM, Dillehay LE, Williams JA, Tabassi K, Brem H, Lee DJ.
    Radiat Oncol Investig; 1998; 6(2):63-70. PubMed ID: 9572682
    [Abstract] [Full Text] [Related]

  • 23. The combined use of 131I-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo.
    Langmuir VK, Mendonca HL.
    Radiat Res; 1992 Dec; 132(3):351-8. PubMed ID: 1475358
    [Abstract] [Full Text] [Related]

  • 24. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors.
    Hicks KO, Siim BG, Pruijn FB, Wilson WR.
    Radiat Res; 2004 Jun; 161(6):656-66. PubMed ID: 15161354
    [Abstract] [Full Text] [Related]

  • 25. Hypoxic cell sensitization: low-dose intrinsic radiosensitivity is predictive for etanidazole efficacy in a panel of human tumour cell lines.
    Wouters BG, Sy AM, Skarsgard LD.
    Int J Radiat Biol; 1996 Dec; 70(6):719-33. PubMed ID: 8980670
    [Abstract] [Full Text] [Related]

  • 26. SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures.
    Biedermann KA, Wang J, Graham RP, Brown JM.
    Br J Cancer; 1991 Mar; 63(3):358-62. PubMed ID: 2003976
    [Abstract] [Full Text] [Related]

  • 27. Characterization of a CHO cell line resistant to killing by the hypoxic cell cytotoxin SR 4233.
    Giaccia AJ, Biedermann KA, Tosto LM, Minchinton AI, Kovacs MS, Brown JM.
    Int J Radiat Oncol Biol Phys; 1992 Mar; 22(4):681-4. PubMed ID: 1544836
    [Abstract] [Full Text] [Related]

  • 28. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
    Dorie MJ, Menke D, Brown JM.
    Int J Radiat Oncol Biol Phys; 1994 Jan 01; 28(1):145-50. PubMed ID: 8270435
    [Abstract] [Full Text] [Related]

  • 29. Novel poly (ADP-ribose) polymerase inhibitor, AZD2281, enhances radiosensitivity of both normoxic and hypoxic esophageal squamous cancer cells.
    Zhan L, Qin Q, Lu J, Liu J, Zhu H, Yang X, Zhang C, Xu L, Liu Z, Cai J, Ma J, Dai S, Tao G, Cheng H, Sun X.
    Dis Esophagus; 2016 Apr 01; 29(3):215-23. PubMed ID: 25604309
    [Abstract] [Full Text] [Related]

  • 30. Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.
    Minchinton AI, Brown JM.
    Br J Cancer; 1992 Dec 01; 66(6):1053-8. PubMed ID: 1457345
    [Abstract] [Full Text] [Related]

  • 31. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
    Brown JM, Lemmon MJ.
    Cancer Res; 1990 Dec 15; 50(24):7745-9. PubMed ID: 2253217
    [Abstract] [Full Text] [Related]

  • 32. The effect of low pH and hypoxia on the cytotoxic effects of SR4233 and mitomycin C in vitro.
    Skarsgard LD, Vinczan A, Skwarchuk MW, Chaplin DJ.
    Int J Radiat Oncol Biol Phys; 1994 May 15; 29(2):363-7. PubMed ID: 8195034
    [Abstract] [Full Text] [Related]

  • 33. Therapeutic targets in radiotherapy.
    Brown JM.
    Int J Radiat Oncol Biol Phys; 2001 Feb 01; 49(2):319-26. PubMed ID: 11173124
    [Abstract] [Full Text] [Related]

  • 34. Increased radiosensitivity with chronic hypoxia in four human tumor cell lines.
    Zölzer F, Streffer C.
    Int J Radiat Oncol Biol Phys; 2002 Nov 01; 54(3):910-20. PubMed ID: 12377345
    [Abstract] [Full Text] [Related]

  • 35. Reoxygenation and rehypoxiation in the SCCVII mouse tumor.
    Kim IH, Brown JM.
    Int J Radiat Oncol Biol Phys; 1994 Jun 15; 29(3):493-7. PubMed ID: 8005805
    [Abstract] [Full Text] [Related]

  • 36. SR-4233 (Tirapazamine) acts as an uncoupler of oxidative phosphorylation in human MCF-7 breast carcinoma cells.
    Ara G, Coleman CN, Teicher BA.
    Cancer Lett; 1994 Oct 14; 85(2):195-203. PubMed ID: 7954337
    [Abstract] [Full Text] [Related]

  • 37. Oleanolic acid enhances the radiosensitivity of tumor cells under mimetic hypoxia through the reduction in intracellular GSH content and HIF-1α expression.
    Qi R, Jin W, Wang J, Yi Q, Yu M, Xu S, Jin W.
    Oncol Rep; 2014 May 14; 31(5):2399-406. PubMed ID: 24604140
    [Abstract] [Full Text] [Related]

  • 38. Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines.
    Britten RA, Evans AJ, Allalunis-Turner MJ, Pearcey RG.
    Int J Radiat Oncol Biol Phys; 1996 Jan 15; 34(2):367-74. PubMed ID: 8567337
    [Abstract] [Full Text] [Related]

  • 39. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia.
    Gandara DR, Lara PN, Goldberg Z, Le QT, Mack PC, Lau DH, Gumerlock PH.
    Semin Oncol; 2002 Feb 15; 29(1 Suppl 4):102-9. PubMed ID: 11894020
    [Abstract] [Full Text] [Related]

  • 40. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine.
    Beck R, Röper B, Carlsen JM, Huisman MC, Lebschi JA, Andratschke N, Picchio M, Souvatzoglou M, Machulla HJ, Piert M.
    J Nucl Med; 2007 Jun 15; 48(6):973-80. PubMed ID: 17536108
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.